Beth Y. Karlan
Karlan, Beth Y.
Karlan, Beth Young.
Karlan, Beth Y. (Beth Young)
VIAF ID: 315218198 (Personal)
Permalink: http://viaf.org/viaf/315218198
Preferred Forms
- 100 0 _ ‡a Beth Y. Karlan
- 200 _ | ‡a Karlan ‡b Beth Y.
- 100 1 _ ‡a Karlan, Beth Y.
-
-
-
-
-
- 100 1 _ ‡a Karlan, Beth Y. ‡q (Beth Young)
-
- 100 1 _ ‡a Karlan, Beth Young
- 100 1 _ ‡a Karlan, Beth Young
-
4xx's: Alternate Name Forms (5)
Works
Title | Sources |
---|---|
BRCA1 i BRCA2 : badanie genetyczne i co dalej | |
Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. | |
Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome | |
Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types | |
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer | |
Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT. | |
Gynecologic oncology : clinical practice & surgical atlas | |
History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report | |
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. | |
Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer | |
Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus | |
Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers. | |
The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. | |
Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration | |
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers | |
Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK. | |
Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome | |
Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein | |
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500 | |
Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers | |
Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling | |
Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening | |
Multiple gestation | |
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer | |
Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations. | |
Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk | |
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. | |
No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival | |
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers | |
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study | |
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS | |
Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility | |
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer | |
Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker | |
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients | |
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants | |
Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer | |
PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations | |
Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium | |
Profiling the perpetrator | |
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia | |
Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition | |
Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States). | |
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer | |
Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation. | |
Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10 | |
rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology | |
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. | |
Shared heritability and functional enrichment across six solid cancers | |
Surgery for ovarian cancer : principles and practice | |
Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers | |
Transcriptome-wide association study of breast cancer risk by estrogen-receptor status | |
Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation | |
Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer | |
Tumorgrafts as in vivo surrogates for women with ovarian cancer. | |
Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women | |
Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility | |
Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer | |
Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer |